Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 657 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR ESMO Launches First Congress on Artificial Intelligence and Digital Oncology: A... November 12, 2025 FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer October 15, 2024 Can cancer cells communicate? February 28, 2023 New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers May 31, 2018 Load more HOT NEWS Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line... Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... Breast Cancer Survivor Fights Back After Instagram Bans Photos of Her... Tables Turned
